BioCentury This Week

9

BioCentury's streaming commentary on biotech industry trends, plus interviews with KOLs.

For three decades, BioCentury has helped biopharma executives and investors make business-critical decisions and build larger networks with peers across the innovation ecosystem.

More
Recent Episodes
  • Ep. 300 - Biotech’s $13B Deal Day, ASCO's Hot Targets, Drug Pricing Threat
    Jun 2, 2025 – 38:48
  • Ep. 299 - ASCO, EpCAM, Rocket & HK IPOs
    May 27, 2025 – 30:37
  • Ep. 298 - Takeaways from the 25th Bio€quity Europe
    May 22, 2025 – 38:53
  • Ep. 297 - European Biotech's Moment? Plus: Biomarin, Boston Deals & Novo Nordisk CEO
    May 19, 2025 – 35:58
  • Ep. 296 - Trends in Obesity, Vinay Prasad at FDA, Ovarian Cancer Insights
    May 12, 2025 – 33:10
  • Ep. 295 - Bio€quity Europe 2025 Preview
    May 8, 2025 – 28:34
  • Ep. 294 - AACR Spotlight on SMARCA2 degraders. Plus: David Baker, Drug Pricing
    May 5, 2025 – 30:35
  • Ep. 293 - Tau Time for Alzheimer's. Plus: FDA Delays, Merck's $4B Deal, HK IPOs
    Apr 28, 2025 – 31:05
  • Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview
    Apr 25, 2025 – 25:51
  • Ep. 291 - Grand Rounds - U.S. Preview
    Apr 24, 2025 – 31:02
  • Ep. 290 - Biotech Survey Sees Tough Days Ahead. Plus: FDA, China Speed
    Apr 21, 2025 – 38:10
  • Ep. 289 - Replacing Animal Models. Plus: RFK Jr. & FDA
    Apr 14, 2025 – 36:55
  • Ep. 288 - FDA and Tariffs Turmoil, and AACR Preview
    Apr 7, 2025 – 26:34
  • Ep. 287 - The Bear is Back: Marks’ Ouster, Tariffs and a Tumbling XBI
    Mar 31, 2025 – 25:46
  • Ep. 286 - Sofinnova’s Pan-European Accelerator, China Biotechs, Trump Tariffs
    Mar 24, 2025 – 24:30
  • Ep. 285 - BIO's Trump 2.0 Plan. Plus: Autoimmune CAR Ts & Telix's Radiopharma Play
    Mar 17, 2025 – 28:26
  • Ep. 284 - Takeaways from the East-West Summit
    Mar 11, 2025 – 41:27
  • Ep. 283 - Makary’s FDA Agenda, Amylin in Obesity and Life After DEI
    Mar 10, 2025 – 31:30
  • Ep. 282 - CRISPR Lessons: Plus, AbbVie Enters Obesity
    Mar 3, 2025 – 23:46
  • Ep. 281 - Roche Reboot and 5 Things on Trump 2.0
    Feb 24, 2025 – 22:12
  • Ep. 280 - China Competition. Plus: FDA Firings and Biotech IPOs
    Feb 18, 2025 – 27:52
  • Ep. 279 - East-West Summit Preview
    Feb 14, 2025 – 29:54
  • Ep. 278 - Trump 2.0’s Impact on FDA, NIH. Plus: Precision Medicine
    Feb 10, 2025 – 26:14
  • Ep. 277 - Asia's NewCo Model, FDA Tipping Point, Vertex's Pain Drug
    Feb 3, 2025 – 25:03
  • Ep. 276 - Precision Neuropsychiatry Spotlight With ICON's Peter Schueler
    Jan 31, 2025 – 21:07
  • Ep. 275 - Series As & Innovation. Plus: Rocky Transition at FDA, NIH
    Jan 27, 2025 – 33:09
  • Ep. 274 - 2025 Biotech Preview: Markets, Catalysts and AI
    Jan 21, 2025 – 36:21
  • Ep. 273 - JPM 2025 Wrap: Sunny Skies & Megarounds
    Jan 16, 2025 – 22:21
  • Ep. 272 - JPM Deal Buzz & Rep. Auchincloss’ Take on Biopharma
    Jan 13, 2025 – 27:29
  • Ep. 271 - Biotech in the New Year. Plus: Beyond Biosecure
    Jan 6, 2025 – 34:54
  • Ep. 270 - Temple’s FDA Legacy. Plus: Chinese Innovation & Novo Obesity Data
    Dec 30, 2024 – 34:56
  • Bonus Content - Trends in Global Biopharma Deals: Lazard’s Kingston and Raine
    Dec 23, 2024 – 34:54
  • Ep. 269 - Trends in VC Funds, Obesity Start-ups and More
    Dec 16, 2024 – 33:14
  • Ep. 268 - Biosecure Setback & Novartis' $1B PTC Deal
    Dec 9, 2024 – 21:49
  • Ep. 267 - Trump's NIH Pick & Multi-targeted CAR Ts
    Dec 2, 2024 – 27:26
  • Ep. 266 - Jefferies Recap, FDA Commissioner & Biosecure Update
    Nov 25, 2024 – 26:32
  • Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals
    Nov 18, 2024 – 29:42
  • Ep. 264 - Prepping for Trump & Alzheimer's Ethics
    Nov 11, 2024 – 29:10
  • Ep. 263 - Alzheimer Insights: Anti-Amyloid Safety & Tau Teaser
    Nov 4, 2024 – 34:38
  • Ep. 262 - EGFR Case Study, FDA & Politics
    Oct 28, 2024 – 23:38
  • Ep. 261 - China Summit: Reinventing Your China Strategy
    Oct 23, 2024 – 31:39
  • Ep. 260 - VC Funds, New Chapter for MS, Wave's Data
    Oct 21, 2024 – 31:18
  • Ep. 259 - Causal Biology and Big Data, Ultra-Rare Drugs at FDA
    Oct 14, 2024 – 33:50
  • Ep. 258 - Breaking the Bear: 4Q Public Markets Preview
    Oct 7, 2024 – 39:44
  • Ep. 257 - Schizophrenia, Sickle Cell Drugs, D.C. Update
    Sep 30, 2024 – 32:19
  • Ep. 256 - ESMO Recap: Keeping TIGIT Alive, Rybrevant & Immunotherapy Anniversary
    Sep 25, 2024 – 26:57
  • Ep. 255 - Pediatric PRVs, Biosecure & Novo's Obesity Miss
    Sep 23, 2024 – 21:49
  • Ep. 254 - Takeaways from Grand Rounds 2024
    Sep 20, 2024 – 34:39
  • Ep. 253 - IPOs, GLP-1 & Obesity, AI & Biotech
    Sep 16, 2024 – 32:58
  • Ep. 252 - Akeso's Bispecific, Vaxcyte & Woodcock's Quality Mindset
    Sep 9, 2024 – 18:37
Recent Reviews
  • Ios9 problem
    terrific summaries capturing the news in this fast-moving space
    LOVE this weekly look at what is happening in biotech, both deep dives into the science itself plus the regulatory/legislative challenges and more. All the regulars are deeply knowledgeable and Jeff Cranmer’s levity as host makes the pod enjoyable and digestible--you really do feel like you have a seat at their editorial meetings. GREAT recaps of the news and in ~30 min or less, I look forward to listening each week!
  • Surfrider182
    Great insights and wisdom!
    Awesome helps me and my team navigate efficiently
  • Pretty Kitty 2
    Simone Fishburn!!!!
    Simone Fishburn is so well spoken and such a tremendous host. Need more of her in our lives !!
Disclaimer: The podcast and artwork on this page are property of the podcast owner, and not endorsed by UP.audio.